Icagen Inactive 10-K2010 FY Annual report

Filed: 9 Mar 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acknowledged, agonist, AGTC, appeal, assigned, ASU, blocker, cap, certified, consideration, cyclooxygenase, deliverable, downturn, economy, factor, fifteen, fractional, gene, hearing, McNicoll, microdose, MLV, NOL, onset, Optionee, oversubscribed, panel, partner, predefined, recovered, recovery, rectified, refractory, residual, retroactively, spread, subtype, taxpayer, timeline, underway, Vlak, VSOE

Removed: accelerating, accessiblein, accredited, accurately, acquiree, aggregating, airway, Albany, assumed, atrial, attribute, bankruptcy, Canada, category, cessation, classify, clinically, CMCC, coincide, confirmed, construct, decade, decided, demonstratedin, derecognition, description, designated, designation, diligent, dissolution, DMC, earn, endpoint, enriched, entry, epithelial, equally, examination, examined, explore, faith, fibrillation, GlaxoSmithKline, goodwill, halted, Head, hematologic, Hetherington, IMS, induced, inhalation, inhaled, Inhibitex, inhibitor, Jude, label, lack, LLP, lung, matched, mathematical, measure, measuring, migration, mild, modification, negotiation, noncontrolling, nonprovisional, Note, penalty, prevention, prospectively, reached, recommended, refund, reliability, resolution, seminar, Seth, settlement, shareholder, sharing, showed, silico, St, substitute, sustained, Tennessee, territory, thereon, threshold, timetable, unauthorized, unqualified, unsuccessful, validated, validating, veterinary, Wellcome

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Icagen similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 10.7

ICAGEN, INC.

Summary of 2011 Bonus Targets

Executive Officer 2011 Bonus Targets


Executive Officer	Bonus Targets for 2011
P. Kay Wagoner, Ph.D., Chief Executive Officer and President		Up to 50% of base salary
Richard D. Katz, M.D., Executive Vice President, Finance and Corporate Development, Chief Financial Officer and Treasurer		Up to 40% of base salary

Cash bonuses for Dr. Wagoner and Dr. Katz for 2011 will be based on the achievement of specified corporate performance objectives. The corporate performance objectives for 2011 are progression of research and clinical development programs; increasing shareholder confidence; improving financial stability through corporate and business development strategies; and achieving top ethical, financial, legal, reporting and compliance standards. The actual amount of such cash bonuses, if any, will be determined in the discretion of the Compensation Committee, subject to the maximum bonus targets shown above. The Compensation Committee will evaluate the Company’s and each executive’s performance against the objectives listed above from time to time during 2011, and may, in its discretion, approve the payment of any bonuses in one or more installments during 2011 or in early 2012.